ZA912490B - Antibody conjugates for treatment of neoplastic disease - Google Patents

Antibody conjugates for treatment of neoplastic disease

Info

Publication number
ZA912490B
ZA912490B ZA912490A ZA912490A ZA912490B ZA 912490 B ZA912490 B ZA 912490B ZA 912490 A ZA912490 A ZA 912490A ZA 912490 A ZA912490 A ZA 912490A ZA 912490 B ZA912490 B ZA 912490B
Authority
ZA
South Africa
Prior art keywords
treatment
neoplastic disease
antibody conjugates
zme
antibody
Prior art date
Application number
ZA912490A
Other languages
English (en)
Inventor
Michael G Rosenblum
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of ZA912490B publication Critical patent/ZA912490B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6821—Plant heterodimeric toxins, e.g. abrin or modeccin
    • A61K47/6823—Double chain ricin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA912490A 1990-04-19 1991-04-04 Antibody conjugates for treatment of neoplastic disease ZA912490B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51092390A 1990-04-19 1990-04-19

Publications (1)

Publication Number Publication Date
ZA912490B true ZA912490B (en) 1992-12-30

Family

ID=24032743

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA912490A ZA912490B (en) 1990-04-19 1991-04-04 Antibody conjugates for treatment of neoplastic disease

Country Status (23)

Country Link
US (1) US20050214307A1 (fr)
EP (1) EP0525119B1 (fr)
JP (1) JP3340127B2 (fr)
KR (1) KR100212372B1 (fr)
CN (1) CN1071579C (fr)
AT (1) ATE164078T1 (fr)
AU (1) AU650267B2 (fr)
CA (1) CA2079902C (fr)
DE (1) DE69129109T2 (fr)
DK (1) DK0525119T3 (fr)
ES (1) ES2113376T3 (fr)
FI (1) FI104234B1 (fr)
HK (1) HK1008418A1 (fr)
IE (1) IE62496B1 (fr)
IL (1) IL97776A (fr)
NO (1) NO317485B1 (fr)
NZ (1) NZ237688A (fr)
PT (1) PT97423B (fr)
RU (1) RU2119352C1 (fr)
SA (1) SA91120208B1 (fr)
TW (1) TW211573B (fr)
WO (1) WO1991016071A1 (fr)
ZA (1) ZA912490B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
CA2072249C (fr) * 1991-06-28 2003-06-17 Saiko Hosokawa Anticorps monoclonal humain liant specifiquement a la surface d'un antigene des membranes des cellules cancereuses
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5632982A (en) * 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
EP1572170A4 (fr) * 2002-06-12 2007-02-28 Res Dev Foundation Immunotoxine servant d'agent therapeutique et ses utilisations
US20060057145A1 (en) * 2002-10-25 2006-03-16 Government Of The United States Of America As Represented By The Secretary, Dept. Of Health Methods to prevent tumor recurrence by blockade of tgf-beta
EP1855724A2 (fr) * 2005-02-01 2007-11-21 Research Development Foundation Proteines de fusion blys (stimulatrices des lymphocytes b) pour cibler le recepteur blys et methodes pour le traitement des maladies proliferatives des cellules b
CA2598090A1 (fr) * 2005-02-17 2006-08-24 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Effet synergique d'agent bloquant le tgf-beta et d'agent immunogene sur les tumeurs
WO2007109193A2 (fr) * 2006-03-16 2007-09-27 Health Research Inc. Inhibition de la croissance et de la métastase de cellules souches du cancer du sein
EP2844300B1 (fr) 2012-05-01 2018-10-17 Genentech, Inc. Anticorps anti-pmel17 et immunoconjugués
CN105377307B (zh) 2013-06-24 2019-09-24 Abl生物公司 具有改进的稳定性的抗体-药物缀合物及其用途
BR112017015582A2 (pt) * 2015-01-23 2018-03-13 Helix Biopharma Corp conjugados de anticorpo-urease para propósitos terapêuticos
CN111278978B (zh) 2017-09-08 2023-08-18 新实有限公司 使细菌能够通过葡萄糖依赖性生存力特异性靶向实体肿瘤的核酸系统
CN110455903A (zh) * 2018-05-07 2019-11-15 天士力生物医药股份有限公司 一种注射用重组人尿激酶原杂质分析的梯度电泳检测方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5032521A (en) * 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4962188A (en) * 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5134075A (en) * 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6306626B1 (en) * 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) * 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
CA2074825C (fr) * 1990-12-14 2005-04-12 Daniel J. Capon Chaines chimeriques pour cheminements de signaux de recepteurs
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5513296A (en) * 1994-06-08 1996-04-30 Holmes Products Corp. Air heater with angled PTC heaters producing diverging heated airflow
AU3548799A (en) * 1998-04-03 1999-10-25 Invitrogen Corporation Libraries of expressible gene sequences
WO2001080880A2 (fr) * 2000-04-22 2001-11-01 Stefan Barth Agent apoptotique
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004535202A (ja) * 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
EP1572170A4 (fr) * 2002-06-12 2007-02-28 Res Dev Foundation Immunotoxine servant d'agent therapeutique et ses utilisations

Also Published As

Publication number Publication date
IE62496B1 (en) 1995-02-08
FI104234B (fi) 1999-12-15
IL97776A0 (en) 1992-06-21
JPH06502617A (ja) 1994-03-24
AU7892291A (en) 1991-11-11
EP0525119A4 (en) 1993-09-15
CA2079902A1 (fr) 1991-10-20
TW211573B (fr) 1993-08-21
PT97423A (pt) 1992-01-31
DE69129109T2 (de) 1998-07-02
NO924025L (no) 1992-10-16
ATE164078T1 (de) 1998-04-15
NO317485B1 (no) 2004-11-08
IE911122A1 (en) 1991-10-23
EP0525119B1 (fr) 1998-03-18
PT97423B (pt) 1998-10-30
NZ237688A (en) 1993-01-27
KR100212372B1 (ko) 1999-08-02
KR930700140A (ko) 1993-03-13
CN1071579C (zh) 2001-09-26
FI924605A0 (fi) 1992-10-12
US20050214307A1 (en) 2005-09-29
DK0525119T3 (da) 1998-11-23
CN1055879A (zh) 1991-11-06
JP3340127B2 (ja) 2002-11-05
NO924025D0 (no) 1992-10-16
RU2119352C1 (ru) 1998-09-27
IL97776A (en) 2000-10-31
HK1008418A1 (en) 1999-05-07
DE69129109D1 (de) 1998-04-23
ES2113376T3 (es) 1998-05-01
FI104234B1 (fi) 1999-12-15
FI924605A (fi) 1992-10-12
EP0525119A1 (fr) 1993-02-03
AU650267B2 (en) 1994-06-16
CA2079902C (fr) 2001-08-28
WO1991016071A1 (fr) 1991-10-31
SA91120208B1 (ar) 2006-03-01

Similar Documents

Publication Publication Date Title
ZA912490B (en) Antibody conjugates for treatment of neoplastic disease
JP5926759B2 (ja) 非開裂リンカーを介して連結した細胞結合物質メイタンシノイド複合体を用いて特定の細胞集団を標的とする方法、前記複合体、および前記複合体の製造法
DE3852250T2 (de) Über Thioetherbindungen verknüpfte Immunokonjugate, mit verminderter Toxizität und vermehrter Selektivität.
EP1594542A4 (fr) Conjugues de medicaments anticorps anti-cd70, utilisation desdits conjugues dans le traitement du cancer et des troubles immunitaires
ZA93945B (en) Dual carrier immunogenic construct.
NO885199D0 (no) FremgangsmŸte for fremstilling av monoklonale antistoffkonjugater.
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
PL248202A1 (en) Process for preparing conjugate with chain b of toxin and method of manufacture of cytotoxic composition
BRPI0017590B8 (pt) conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
ES8706965A1 (es) Un metodo de formacion de un conjugado de proteina y quelato metalico
EP0226419A3 (en) Anti-human ovarian cancer immunotoxins and methods of use thereof
GB1446536A (en) Pharmaceutically active compositions
ZA864769B (en) Process and composition for treatment of cancer and non-malignant tumors
Molthoff et al. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F (ab') 2 fragments in experimental ovarian cancer
ES2121881T3 (es) Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores.
FI895005A0 (fi) Immunotoxiner foer behandling och profylax av autoimmuna sjukdomar.
EA200100311A1 (ru) Бифункциональные антитела и их применение для прицельной доставки противоопухолевых средств
TWI265811B (en) Extended type 1 chain glycosphingolipids as tumor-associated antigens
PT100660A (pt) Compostos conjugados uteis para o tratamento de tumores gastrointestinais e composicoes farmaceuticas que os contem